Results 221 to 230 of about 106,790 (296)
The use of different types of networks, alone and in combination, for drug target identification
Current therapeutic approaches often focus on targeting clinical symptoms or peripheral phenotypes rather than the underlying molecular mechanisms, or endophenotypes, that drive diseases. While symptom‐based drugs can alleviate discomfort, they do not necessarily alter disease progression and may overlook opportunities for prevention or early ...
Paolo Parini
wiley +1 more source
Efficacy of electroconvulsive therapy in treating auditory verbal hallucinations in a deaf patient with schizophrenia: A case report. [PDF]
Wang J, Li J, Wei YG, Lu XX, Zhang ZH.
europepmc +1 more source
Abstract Background and purpose Clozapine, an approved antipsychotic for treatment‐resistant schizophrenia (TRS), enhances glutamatergic transmission by increasing exocytosis and non‐exocytosis glutamate release; however, its full action remained to be clarified.
Motohiro Okada+2 more
wiley +1 more source
Efficacy and tolerability of pharmacological interventions for schizophrenia non-responsive to prior treatment: a systematic review and network meta-analysis. [PDF]
Samara M+10 more
europepmc +1 more source
ABSTRACT Antipsychotic drugs (APDs) are a diverse class of neuroactive pharmaceuticals increasingly detected in surface and ground waters globally. Some APDs are classified as posing a high environmental risk, due, in part, to their tendency to bioaccumulate in wildlife, including fish.
Gabrielle Wasser‐Bennett+4 more
wiley +1 more source
We appreciate the commentary by Tiffin and Kelleher on our systematic review and meta‐analysis. The CHR‐P paradigm remains one of the most established preventive approaches in mental health. While concerns have been raised regarding the clinical utility of the CHR‐P paradigm, its implementation in specialized services worldwide supports its relevance ...
Gonzalo Salazar de Pablo+4 more
wiley +1 more source